LABORATORY REF. NO.

478853/A
VTU505 - PKDK Sai Gon - Vung Tau - Mindray BS 200E

PHONG KHAM DA KHOA SAI GON - VUNG TAU

MONTHLY CLINICAL CHEMISTRY

CYCLE 16 SAMPLE 8

Explanation of codes used in this report

R - Results removed due to reconstitution error

N - No result returned
C - Result corrected

Authorised by: Stephen Doherty, RIQAS Manager Issue No: 1 Issue Date: 29/08/2019

BÔ. Y TÊ´
ÐAI ´ `
. HOC . Y DUOC . THÀNH PHÔ HÔ CHÍ MINH
, ,

A
?

TRUNG TÂM KIÊM CHUÂN CHÂT

?
´ LUONG XÉT NGHIÊM . Y HOC
, ,
. .
Ðia
. ch
?
1 : ´
sô 131 Nguyên
~
Chí Thanh, Phuong
,
`
,
9, Quân
. 5, TPHCM.
Email1: TRUNGTAMKIEMCHUAN@GMAIL.COM

A
Email2: EQA.QCC.UMP@GMAIL.COM
Website: WWW.QCCUMP.COM
Page 1
Ðiên
. thoai:
. 028.38531058 - Fax: 028.38531049
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 478853/A CYCLE 16 SAMPLE 8 26/08/2019
Mean for Comparison

I 159.067

I 157.801

I 156.249

I 152.058

I 157.143

I 134.898

I 155.908
I 37.911

I 38.657

I 38.379

I 37.118

I 42.113

I 44.180

I 42.356

I 42.547

I 34.806

I 43.010

I 12.956

I 33.897

I 38.087
ALT (GPT), U/l @ 37°C
>+3

N Mean CV% Um SDPA Exc.

+2

All Methods 5427 37.108 10.1 0.06 3.27 391

Tris buffer without P5P 4191 36.302 9.1 0.06 3.20 344 +11

Standard Deviation
Mindray BS Series 187 38.087 9.6 0.33 3.36 13
0

-1
Your Result 31.500 SDI -1.96
RMSDI Too Few
-2

Mean for Comparison 38.087 TS 42

RMTS Too Few <-3

N N N N N N N N N N N N N N 3 4 5 6 7 8

%DEV -17.3 Sample Number

RM%DEV Too Few TDPA = 14.5%

120

110

100

Acceptable limits derived from Biological Variation 27.48 % 90

Acceptable limits of performance for RIQAS 14.50 % 80

70

Target Score
TS & %DEV outside limits 60

50

40

30

20

10

N N N N N N N N N N N N N N 3 4 5 6 7 8

900 Sample Number

800
>= 30

700
20
Number of Laboratories

600

10
500
% Deviation

400 0

300
-10

200
-20

100

<= -30

0 N N N N N N N N N N N N N N 3 4 5 6 7 8
Sample Number
< 27.22 30.04 32.87 35.69 38.52 41.34 44.16 46.99 >
U/l
>= 30

Method N Mean CV% Um 20

Tris buffer without P5P 4191 36.302 9.1 0.06

Tris buffer with P5P 375 40.401 11.2 0.29 10

Beckman Mod. IFCC Ref. without P5P 304 38.653 5.6 0.16
% Deviation

Siemens/Dade standard nonIFCC correlated 153 43.759 5.2 0.23

Ortho Vitros MicroSlide Systems 145 42.699 11.6 0.51 0

Colorimetric 37 36.400 11.4 0.85

Agappe - IFCC 32 39.502 11.2 0.98
Ortho Vitros MicroSlide visible 31 38.937 3.8 0.33 -10

Other Dry Chemistry 25 36.098 10.2 0.92

Phosphate buffer, DGKC 23 38.559 8.4 0.84
Tris buffer, SCE 23 36.558 9.0 0.86 -20

Beckman IFCC Ref. with P5P 21 38.530 8.3 0.88

Tris buffer with P5P, NVKC 20 36.863 10.8 1.11
Beckman (Extinction Coefficient) 5 38.840 7.6 1.66 <= -30

Vitros DT60/DT60 II/DTSC II 2 43.500 1.6 0.62 0 20 40 60 80 100 120 140 160

Concentration

Issue No: 1 Issue Date: 29/08/2019 Page 2

A A
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 478853/A CYCLE 16 SAMPLE 8 26/08/2019
Mean for Comparison

I 285.274

I 276.776

I 290.975

I 661.345

I 304.072

I 613.791

I 314.377
I 84.206

I 81.605

I 82.738

I 82.989

I 86.802

I 86.032

I 83.495

I 86.937

I 89.589

I 84.923

I 20.061

I 92.234

I 92.437
Amylase, Total, U/l @ 37°C
>+3

N Mean CV% Um SDPA Exc.

+2

All Methods 3546 92.199 8.3 0.16 8.35 333

Other 2-chloro-pNPG3 951 89.460 10.4 0.38 8.10 87 +11

Standard Deviation
Mindray BS Series 60 92.437 8.2 1.22 8.37 7
0

-1
Your Result 73.900 SDI -2.21
RMSDI Too Few
-2

Mean for Comparison 92.437 TS 37

RMTS Too Few <-3

N N N N N N N N N N N N N N 3 4 5 6 7 8

%DEV -20.1 Sample Number

RM%DEV Too Few TDPA = 14.9%

120

110

100

Acceptable limits derived from Biological Variation 14.6 % 90

Acceptable limits of performance for RIQAS 14.90 % 80

70

Target Score
SDI in bottom 5% of peer group 60

TS & %DEV outside limits 50

40

30

20

10

N N N N N N N N N N N N N N 3 4 5 6 7 8

Sample Number
600

>= 30

500

20
Number of Laboratories

400

10
% Deviation

300
0

200 -10

-20
100

<= -30

0 N N N N N N N N N N N N N N 3 4 5 6 7 8
Sample Number
< 72.16 77.88 83.61 89.33 95.06 100.78 106.51 112.23 >
U/l
>= 30

Method N Mean CV% Um 20

Other 2-chloro-pNPG3 951 89.460 10.4 0.38

Roche liquid stable pNPG7 629 90.671 2.7 0.12 10

Beckman Olympus blocked pNPG7 321 94.517 5.0 0.33

% Deviation

Siemens/Dade Behring 2-chloro-pNPG3 242 100.800 2.0 0.16

Other - blocked pNPG7 140 92.109 8.5 0.83 0

Ortho Vitros MicroSlide Systems 129 70.371 6.6 0.51

Beckman CNPG3 (Master Cal) 121 86.301 4.2 0.41
Abbott Architect cal factor 3431 102 98.974 3.9 0.47 -10

Randox Liquid Ethylidene pNPG7 99 98.258 6.6 0.82

Bayer - blocked pNPG7 82 95.051 3.6 0.47
Other non blocked pNPG7 77 92.368 6.8 0.90 -20

Other 2-chloro-pNP-linked sub. 68 91.706 7.0 0.98

Wiener Amilokit (AU/dl) 67 76.555 24.0 2.80
Roche Integra 2-chloro-pNPG7 66 92.567 3.1 0.44 <= -30

Beckman Synchron AMY7 56 95.955 3.6 0.57 10 110 210 310 410 510 610
Abbott Architect cal factor 3806 47 103.356 5.2 0.98
Concentration
pNP Maltotrioside substrates 44 94.253 7.7 1.37
I.L. 2-chloro-pNPG3 36 94.868 5.7 1.12

A
Other Dry Chemistry 29 94.169 5.8 1.28
Other Roche 2-chloro-pNPG7 31 90.905 2.1 0.44
Randox Lyo. Ethylidene pNPG7 31 95.143 4.9 1.05

Issue No: 1 Issue Date: 29/08/2019 Page 3

A
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 478853/A CYCLE 16 SAMPLE 8 26/08/2019
Mean for Comparison

I 150.856

I 149.002

I 155.300

I 192.631

I 154.649

I 179.657

I 157.779
I 39.641

I 35.256

I 35.093

I 38.345

I 40.485

I 36.741

I 38.805

I 40.649

I 33.788

I 37.905

I 11.012

I 32.494

I 38.849
AST (GOT), U/l @ 37°C
>+3

N Mean CV% Um SDPA Exc.

+2

All Methods 5240 38.626 11.1 0.07 3.24 541

Tris buffer without P5P 4221 37.668 8.3 0.06 3.16 349 +11

Standard Deviation
Mindray BS Series 180 38.849 8.0 0.29 3.26 19
0

-1
Your Result 33.500 SDI -1.64
RMSDI Too Few
-2

Mean for Comparison 38.849 TS 50

RMTS Too Few <-3

N N N N N N N N N N N N N N 3 4 5 6 7 8

%DEV -13.8 Sample Number

RM%DEV Too Few TDPA = 13.8%

120

110

100

Acceptable limits derived from Biological Variation 16.69 % 90

Acceptable limits of performance for RIQAS 13.80 % 80

70

Target Score
60

50

40

30

20

10

N N N N N N N N N N N N N N 3 4 5 6 7 8

Sample Number

1000

>= 20

800 15
Number of Laboratories

10

600 5
% Deviation

400
-5

-10

200
-15

<= -20

0 N N N N N N N N N N N N N N 3 4 5 6 7 8
Sample Number
< 27.38 30.59 33.80 37.02 40.23 43.44 46.65 49.86 >
U/l
>= 20

15
Method N Mean CV% Um
10
Tris buffer without P5P 4221 37.668 8.3 0.06
Beckman Mod. IFCC Ref. without P5P 316 40.274 4.7 0.13
5
Tris buffer with P5P 292 50.692 11.0 0.41
% Deviation

Ortho Vitros MicroSlide visible 166 53.000 3.5 0.18

Siemens/Dade standard non IFCC corr. 154 51.901 6.3 0.33 0

Colorimetric 36 39.130 8.4 0.69

Agappe - IFCC 33 44.280 12.6 1.22 -5
Other Dry Chemistry 25 38.284 13.2 1.27
Phosphate buffer, DGKC 26 40.023 11.3 1.11
-10
Tris buffer, SCE 22 38.835 6.7 0.70
Tris buffer with P5P, NVKC 21 37.600 6.8 0.70
Beckman IFCC Ref. with P5P 6 53.033 2.9 0.80 -15

Beckman (Extinction Coefficient) 6 38.517 10.2 2.00

Vitros DT60/DT60 II/DTSC II 2 41.500 29.0 10.62 <= -20

0 20 40 60 80 100 120 140 160 180

Concentration

Issue No: 1 Issue Date: 29/08/2019 Page 4

A A
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 478853/A CYCLE 16 SAMPLE 8 26/08/2019
Mean for Comparison

Cholesterol, mmol/l

I 4.071

I 7.565

I 4.053

I 7.587

I 4.037

I 4.096

I 3.880

I 4.170

I 6.967

I 4.093

I 8.121

I 3.873

I 3.869

I 7.246

I 4.087

I 2.633

I 6.715

I 3.885

I 7.387

I 4.036
>+3

N Mean CV% Um SDPA Exc.

+2

All Methods 4988 4.001 4.5 0.00 0.23 543

Cholesterol Oxidase - Abell Kendall 4189 4.015 4.1 0.00 0.23 408 +11

Standard Deviation
Mindray BS Series 195 4.036 4.0 0.01 0.23 18
0

-1
Your Result 3.720 SDI -1.37
RMSDI Too Few
-2

Mean for Comparison 4.036 TS 58

RMTS Too Few <-3

N N N N N N N N N N N N N N 3 4 5 6 7 8

%DEV -7.8 Sample Number

RM%DEV Too Few TDPA = 9.4%

120

110

100

Acceptable limits derived from Biological Variation 9.01 % 90

Acceptable limits of performance for RIQAS 9.40 % 80

70

Target Score
60

50

40

30

20

10

N N N N N N N N N N N N N N 3 4 5 6 7 8

Sample Number

800
>= 15

700
10
Number of Laboratories

600

5
500
% Deviation

400 0

300
-5

200
-10

100

<= -15

0 N N N N N N N N N N N N N N 3 4 5 6 7 8
Sample Number
< 3.53 3.66 3.80 3.93 4.06 4.20 4.33 4.46 >
mmol/l
>= 15

Method N Mean CV% Um 10

Cholesterol Oxidase - Abell Kendall 4189 4.015 4.1 0.00

Cholesterol Oxidase - IDMS 379 4.018 3.7 0.01 5

Siemens Dimension 208 3.457 2.9 0.01

% Deviation

Ortho Vitros MicroSlide Systems 169 3.854 3.2 0.01

Cholesterol Dehydrogenase 40 4.056 4.6 0.04 0

Agappe - CHOD-PAP 31 3.898 6.1 0.05

Other Dry Chemistry 25 4.003 7.1 0.07
Dimension - non Siemens reagents 2 3.765 10.0 0.33 -5

Vitros DT60/DT60 II/DTSC II 2 3.720 3.0 0.10

-10

<= -15

0 1 2 3 4 5 6 7 8 9

Concentration

Issue No: 1 Issue Date: 29/08/2019 Page 5

A A
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 478853/A CYCLE 16 SAMPLE 8 26/08/2019
Mean for Comparison

I 131.576

I 354.767

I 124.252

I 355.136

I 124.053

I 128.795

I 123.417

I 122.762

I 363.803

I 128.917

I 550.796

I 123.698

I 136.888

I 360.707

I 130.790

I 570.177

I 139.651

I 354.152

I 125.342
I 78.229
Creatinine, umol/l
>+3

N Mean CV% Um SDPA Exc.

+2

All Methods 5415 127.157 5.8 0.12 9.59 513

Alkaline picrate no deproteinisation 1800 127.154 6.5 0.24 9.59 164 +11

Standard Deviation
Mindray BS Series 64 125.342 6.4 1.25 9.45 2
0

-1
Your Result 135.000 SDI 1.02
RMSDI Too Few
-2

Mean for Comparison 125.342 TS 71

RMTS Too Few <-3

N N N N N N N N N N N N N N 3 4 5 6 7 8

%DEV 7.7 Sample Number

RM%DEV Too Few TDPA = 12.4%

120

110

100

Acceptable limits derived from Biological Variation 8.87 % 90

Acceptable limits of performance for RIQAS 12.40 % 80

70

Target Score
60

50

40

30

20

10

N N N N N N N N N N N N N N 3 4 5 6 7 8

Sample Number

900
>= 15

800

10
700
Number of Laboratories

600 5
% Deviation

500
0

400

-5
300

200
-10

100

<= -15

0 N N N N N N N N N N N N N N 3 4 5 6 7 8
Sample Number
< 107.88 113.39 118.89 124.40 129.91 135.41 140.92 146.43 >
umol/l
>= 15

Method N Mean CV% Um 10

Alkaline picrate no deproteinisation 1800 127.154 6.5 0.24

Jaffe rate blanked 1251 127.411 5.8 0.26 5

Jaffe rate blanked comp. (-26umol/l) 510 128.487 4.9 0.35

% Deviation

Jaffe rate comp. (-18umol/l) 457 122.828 5.2 0.38

Roche Creatinine Plus 237 131.420 3.5 0.37 0

Enzymatic UV method (340nm) 219 128.285 5.0 0.54

Creatinine PAP method 208 128.275 4.7 0.52
IDMS traceable 174 127.444 4.4 0.53 -5

Vitros, IDMS traceable 145 122.027 3.0 0.38

Other enzymatic methods 119 128.495 3.4 0.51
Alkaline picrate with deproteinisation 104 127.541 5.6 0.87 -10

Jaffe rate blanked comp. (-33umol/l) 85 126.238 7.0 1.20

Other Dry Chemistry 37 124.264 5.9 1.50
Agappe - JAFFE'S KINETIC 20 130.413 7.5 2.72 <= -15

Agappe - ENZYMATIC 12 126.232 7.1 3.25 30 130 230 330 430 530
Vitros DT60/DT60 II/DTSC II 13 122.717 4.1 1.76
Concentration

Issue No: 1 Issue Date: 29/08/2019 Page 6

A A
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 478853/A CYCLE 16 SAMPLE 8 26/08/2019
Mean for Comparison

I 15.633

I 15.492

I 15.852

I 20.865

I 15.973

I 20.122

I 15.474
Glucose, mmol/l

I 6.268

I 6.279

I 6.286

I 6.212

I 6.457

I 6.514

I 6.261

I 6.399

I 6.164

I 6.267

I 2.233

I 6.132

I 6.340
>+3

N Mean CV% Um SDPA Exc.

+2

All Methods 5489 6.166 4.1 0.00 0.32 474

Glucose oxidase 2442 6.209 5.6 0.01 0.32 191 +11

Standard Deviation
Mindray BS Series 200 6.340 4.5 0.03 0.33 13
0

-1
Your Result 6.200 SDI -0.43
RMSDI Too Few
-2

Mean for Comparison 6.340 TS 109

RMTS Too Few <-3

N N N N N N N N N N N N N N 3 4 5 6 7 8

%DEV -2.2 Sample Number

RM%DEV Too Few TDPA = 8.5%

120

110

100

Acceptable limits derived from Biological Variation 6.96 % 90

Acceptable limits of performance for RIQAS 8.50 % 80

70

Target Score
60

50

40

30

20

10

N N N N N N N N N N N N N N 3 4 5 6 7 8

900 Sample Number

800
>= 10

700 8

6
Number of Laboratories

600
4

500
2
% Deviation

0
400

-2
300
-4

200
-6

-8
100

<= -10

0 N N N N N N N N N N N N N N 3 4 5 6 7 8
Sample Number
< 5.50 5.69 5.88 6.07 6.26 6.44 6.63 6.82 >
mmol/l
>= 10

Method N Mean CV% Um

6

Hexokinase 2728 6.154 2.8 0.00 4

Glucose oxidase 2442 6.209 5.6 0.01
Ortho Vitros MicroSlide Systems 166 6.004 2.7 0.02 2
% Deviation

Glucose dehydrogenase 64 6.196 4.7 0.05

Agappe - GOD-PAP 32 6.460 4.1 0.06 0

Oxygen electrode 30 6.129 3.0 0.04

Other Dry Chemistry 26 6.090 4.5 0.07 -2

GOD/02-Beckman method 20 6.137 4.9 0.08

-4
Vitros, DT60/DT60 II 2 5.962 3.3 0.17
-6

-8

<= -10

0 5 10 15 20

Concentration

Issue No: 1 Issue Date: 29/08/2019 Page 7

A A
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 478853/A CYCLE 16 SAMPLE 8 26/08/2019
Mean for Comparison

HDL-Cholesterol, mmol/l

I 1.340

I 2.855

I 1.276

I 2.752

I 1.311

I 1.329

I 1.195

I 1.431

I 2.348

I 1.261

I 2.570

I 1.189

I 1.334

I 2.469

I 1.255

I 1.070

I 2.536

I 1.303

I 2.448

I 1.262
>+3

N Mean CV% Um SDPA Exc.

+2

All Methods 3859 1.273 8.2 0.00 0.15 354

Direct HDL, PEGME 399 1.247 8.9 0.01 0.15 37 +11

Standard Deviation
Mindray BS Series 19 1.262 6.0 0.02 0.15 2
0

-1
Your Result 1.120 SDI -0.93
RMSDI Too Few
-2

Mean for Comparison 1.262 TS 75

RMTS Too Few <-3

N N N N N N N N N N N N N N 3 4 5 6 7 8

%DEV -11.3 Sample Number

RM%DEV Too Few TDPA = 19.9%

120

110

100

Acceptable limits derived from Biological Variation 11.63 % 90

Acceptable limits of performance for RIQAS 19.90 % 80

70

Target Score
60

50

40

30

20

10

N N N N N N N N N N N N N N 3 4 5 6 7 8

Sample Number
700

>= 30

600

20

500
Number of Laboratories

10

400
% Deviation

300

-10

200

-20

100

<= -30

0 N N N N N N N N N N N N N N 3 4 5 6 7 8
Sample Number
< 0.99 1.07 1.15 1.23 1.31 1.38 1.46 1.54 >
mmol/l
>= 30

Method N Mean CV% Um 20

Direct HDL, Roche 4th gen. 925 1.307 3.9 0.00

Direct HDL, Immunoseparation 856 1.235 6.9 0.00 10

Direct HDL, Clearance method 790 1.213 11.8 0.01

% Deviation

HDL Ultra/Accel Selective Detergent 403 1.360 7.5 0.01

Direct HDL, PEGME 399 1.247 8.9 0.01 0

Direct HDL, PPD 270 1.318 8.4 0.01

Vitros dHDL, PTA/MgCl2 direct precip. 123 1.206 4.7 0.01
Other Dry Chemistry 36 1.270 8.9 0.02 -10

Agappe - SELECTIVE INHIBITION 19 1.373 4.3 0.02

Vitros, Magnetic HDL 22 1.215 7.6 0.02
Vitros 5.1 FS Microtip assay 13 1.209 4.0 0.02 -20

<= -30

0.0 0.5 1.0 1.5 2.0 2.5 3.0

Concentration

Issue No: 1 Issue Date: 29/08/2019 Page 8

A A
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 478853/A CYCLE 16 SAMPLE 8 26/08/2019
Mean for Comparison

Trig Total, mmol/l

I 1.084

I 2.841

I 1.095

I 2.868

I 1.094

I 1.082

I 1.076

I 1.115

I 2.748

I 1.184

I 4.556

I 1.084

I 1.104

I 2.737

I 1.183

I 0.284

I 4.104

I 1.105

I 2.960

I 1.172
>+3

N Mean CV% Um SDPA Exc.

+2

All Methods 4908 1.160 5.9 0.00 0.09 474

Lipase/GPO-PAP no correction 3758 1.157 5.5 0.00 0.09 338 +11

Standard Deviation
Mindray BS Series 158 1.172 5.5 0.01 0.09 19
0

-1
Your Result 1.200 SDI 0.31
RMSDI Too Few
-2

Mean for Comparison 1.172 TS 120

RMTS Too Few <-3

N N N N N N N N N N N N N N 3 4 5 6 7 8

%DEV 2.4 Sample Number

RM%DEV Too Few TDPA = 12.6%

120

110

100

Acceptable limits derived from Biological Variation 25.99 % 90

Acceptable limits of performance for RIQAS 12.60 % 80

70

Target Score
60

50

40

30

20

10

N N N N N N N N N N N N N N 3 4 5 6 7 8

Sample Number

800
>= 15

700

10

600
Number of Laboratories

5
500
% Deviation

400 0

300
-5

200
-10

100

<= -15

0 N N N N N N N N N N N N N N 3 4 5 6 7 8
Sample Number
< 0.98 1.03 1.08 1.13 1.18 1.23 1.28 1.34 >
mmol/l
>= 15

Method N Mean CV% Um 10

Lipase/GPO-PAP no correction 3758 1.157 5.5 0.00

Lipase/GK UV. no correction 409 1.156 5.1 0.00 5

Lipase/GPO-PAP, 0.11mmol/l correction 263 1.158 6.0 0.01

% Deviation

Lipase/Glycerol Dehydrogenase 208 1.156 5.1 0.01

Ortho Vitros MicroSlide Systems 165 1.338 3.9 0.01 0

Lipase/GK UV., 0.11 mmol/l correction 54 1.151 5.1 0.01

Agappe - GPO - TOPS 27 1.159 4.2 0.01
Other Dry Chemistry 23 1.243 9.1 0.03 -5

Siemens Dimension 8 1.091 1.9 0.01

Vitros DT60/DT60 II/DTSC II 2 1.227 3.1 0.03
-10

<= -15

0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5

Concentration

Issue No: 1 Issue Date: 29/08/2019 Page 9

A A
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 478853/A CYCLE 16 SAMPLE 8 26/08/2019
Mean for Comparison

I 20.493

I 20.538

I 19.855

I 24.600

I 19.359

I 25.384

I 20.107
Urea, mmol/l

I 7.299

I 7.307

I 7.227

I 7.264

I 7.854

I 7.668

I 7.789

I 7.926

I 7.413

I 7.813

I 2.338

I 7.347

I 7.369
>+3

N Mean CV% Um SDPA Exc.

+2

All Methods 5327 7.286 5.1 0.01 0.54 488

Urease, kinetic 4596 7.302 4.9 0.01 0.54 432 +11

Standard Deviation
Mindray BS Series 178 7.369 5.3 0.04 0.55 20
0

-1
Your Result 7.200 SDI -0.31
RMSDI Too Few
-2

Mean for Comparison 7.369 TS 120

RMTS Too Few <-3

N N N N N N N N N N N N N N 3 4 5 6 7 8

%DEV -2.3 Sample Number

RM%DEV Too Few TDPA = 12.2%

120

110

100

Acceptable limits derived from Biological Variation 15.55 % 90

Acceptable limits of performance for RIQAS 12.20 % 80

70

Target Score
60

50

40

30

20

10

N N N N N N N N N N N N N N 3 4 5 6 7 8

Sample Number

900

>= 15
800

700 10
Number of Laboratories

600
5

500
% Deviation

0
400

300 -5

200
-10

100

<= -15

0 N N N N N N N N N N N N N N 3 4 5 6 7 8
Sample Number
< 6.31 6.59 6.86 7.14 7.42 7.70 7.98 8.25 >
mmol/l
>= 15

Method N Mean CV% Um 10

Urease, kinetic 4596 7.302 4.9 0.01

Urease, end point 312 7.266 6.0 0.03 5

Ortho Vitros MicroSlide Systems 170 6.992 3.0 0.02

% Deviation

Urease, hypochlorite 133 7.370 6.9 0.06

Beckman - Conductivity 31 7.368 4.2 0.07 0

Agappe - UREASE GLDH 26 7.293 5.6 0.10

Other Dry Chemistry 21 7.482 5.8 0.12
O-Phthalaldehyde 4 7.533 1.0 0.05 -5

Agappe - BERTHELOT 4 7.507 9.2 0.43

Diacetyl monoxime 4 7.867 26.6 1.31
Vitros DT60/DT60 II 2 6.912 5.9 0.36 -10

<= -15

0 5 10 15 20 25

Concentration

Issue No: 1 Issue Date: 29/08/2019 Page 10

A A
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 478853/A CYCLE 16 SAMPLE 8 26/08/2019
Mean for Comparison

I 359.414

I 544.965

I 343.054

I 547.201

I 348.481

I 349.579

I 370.393

I 365.028

I 549.993

I 349.104

I 603.427

I 348.155

I 339.554

I 577.665

I 357.205

I 187.340

I 549.592

I 338.700

I 538.562

I 354.035
Uric Acid (Urate), umol/l
>+3

N Mean CV% Um SDPA Exc.

+2

All Methods 4951 348.734 5.0 0.30 22.40 485

Uricase perox. no ascorb. ox. 2216 348.273 5.9 0.50 22.40 218 +11

Standard Deviation
Mindray BS Series 107 354.035 7.7 3.20 22.80 12
0

-1
Your Result 355.000 SDI 0.04
RMSDI Too Few
-2

Mean for Comparison 354.035 TS 120

RMTS Too Few <-3

N N N N N N N N N N N N N N 3 4 5 6 7 8

%DEV 0.3 Sample Number

RM%DEV Too Few TDPA = 10.6%

120

110

100

Acceptable limits derived from Biological Variation 11.97 % 90

Acceptable limits of performance for RIQAS 10.60 % 80

70

Target Score
60

50

40

30

20

10

N N N N N N N N N N N N N N 3 4 5 6 7 8

Sample Number

900

>= 20
800

15
700
Number of Laboratories

10
600

5
500
% Deviation

0
400

-5
300

-10
200

-15
100

<= -20

0 N N N N N N N N N N N N N N 3 4 5 6 7 8
Sample Number
< 303.32 316.29 329.27 342.24 355.22 368.19 381.17 394.14 >
umol/l
>= 20

15
Method N Mean CV% Um
10
Uricase perox. no ascorb. ox. 2216 348.273 5.9 0.50
Uricase Perox. with ascorb. ox 1429 351.034 4.2 0.40
5
Uricase Perox. with ascorb. ox @ 546nm 804 349.628 4.4 0.60
% Deviation

Ortho Vitros MicroSlide Systems 160 334.270 2.4 0.80

Uricase @ 293 nm 152 344.930 2.0 0.70 0

Uricase, catalase 340nm. 114 346.226 2.3 0.90

Other Dry Chemistry 24 362.850 9.3 8.50 -5
Reduction methods 16 358.962 8.0 9.00
Agappe - URICASE - TOPS 15 384.240 5.9 7.20
-10
Agappe - URICASE - PAP 10 365.243 9.9 14.20
Vitros DT60/DT60 II 2 332.550 5.9 17.40
-15

<= -20

90 190 290 390 490 590 690

Concentration

Issue No: 1 Issue Date: 29/08/2019 Page 11

A A
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 478853/A CYCLE 16 SAMPLE 8 26/08/2019

Mean for Your

Analyte Comparison Result SDI RMSDI %DEV RM%DEV TS RMTS Performance

ALT (GPT) 38.087 31.500 -1.96 Too Few -17.3 Too Few 42 Too Few
Amylase, Total 92.437 73.900 -2.21 Too Few -20.1 Too Few 37 Too Few
AST (GOT) 38.849 33.500 -1.64 Too Few -13.8 Too Few 50 Too Few
Cholesterol 4.036 3.720 -1.37 Too Few -7.8 Too Few 58 Too Few
Creatinine 125.342 135.000 1.02 Too Few 7.7 Too Few 71 Too Few
Glucose 6.340 6.200 -0.43 Too Few -2.2 Too Few 109 Too Few
HDL-Cholesterol 1.262 1.120 -0.93 Too Few -11.3 Too Few 75 Too Few
Trig Total 1.172 1.200 0.31 Too Few 2.4 Too Few 120 Too Few
Urea 7.369 7.200 -0.31 Too Few -2.3 Too Few 120 Too Few
Uric Acid (Urate) 354.035 355.000 0.04 Too Few 0.3 Too Few 120 Too Few

ORMSDI N/A ORM%DEV N/A ORMTS N/A

A
END OF REPORT

Issue No: 1 Issue Date: 29/08/2019 Page 12

A